| Scientific Name |
Crizanlizumab
|
|---|---|
| Brand Name |
Adakveo
|
| Risk |
Phase III study (CSEG101A2301) shows no superiority of crizanlizumab over placebo.
|
| Dear Healthcare Professional Communication (DHPC) for Healthcare Professionals |
|